APPA [AKL4] is an investigational medicine that has demonstrated anti-inflammatory effects in a variety of validated animal studies, including the slowing of cartilage in the rat meniscal tear model. Specifically, APPA has demonstrated pain relief from Osteoarthritis (OA), improved functionality and slowed cartilage destruction. Current approved treatments for OA focus on providing patients with pain relief only and are a short-term solution.
APPA directly affects inflammation at its source by regulating intracellular signaling molecules, NFkB and Nrf2. APPA regulates rather than blocking the immune response, allowing host defences to be maintained. (See our R&D pages for more information on how APPA works).
We anticipate that our investigational medicine, APPA, will be differentiated primarily by its tolerability and it’s potential to be used a first-line therapy.
Having successfully passed preclinical toxicology studies, APPA is currently undergoing a Phase I clinical trial at Liverpool University. The trial, led by rheumatologist Professor Robert Moots from the University’s Institute of Ageing and Chronic Disease, is formally investigating APPA’s safety in humans. On completion, a larger Phase II trial will look at efficacy of APPA and an early assessment of disease modification.
APPA has the potential to meet the unfulfilled therapeutic needs of millions of OA sufferers and is also being evaluated for the treatment of other diseases linked to inflammation, including Alzheimer’s Disease, rheumatoid arthritis and scleroderma, a rare connective tissue disease.
We welcome enquiries from potential investors and partners in this development and commercialisation process.